Network Portfolio Roadmap
Submitted by Anonymous (not verified) on 13 March 2025 - 14:26
Network Portfolio Roadmap
High-risk medical devices: consultation procedures and advice
Submitted by Anonymous (not verified) on 13 March 2025 - 13:37
High-risk medical devices: consultation procedures and advice
List of clinical evaluation consultation procedure (CECP) opinions issued for medical devices awaiting finalisation of conformity assessment
Submitted by Anonymous (not verified) on 13 March 2025 - 13:33
List of clinical evaluation consultation procedure (CECP) opinions issued for medical devices awaiting finalisation of conformity assessment
Drug-Eluting stent (DES) - Notified Body 2265 - 10/01/2025 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)
Submitted by Anonymous (not verified) on 13 March 2025 - 13:25
Drug-Eluting stent (DES) - Notified Body 2265 - 10/01/2025 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)
EMEA-000383-PIP04-23
Submitted by Anonymous (not verified) on 13 March 2025 - 12:52
EMEA-000383-PIP04-23
Unregulated advanced therapy medicinal products pose serious risks to health
Submitted by Anonymous (not verified) on 13 March 2025 - 11:00
Unregulated advanced therapy medicinal products pose serious risks to health
Herbal medicinal product: Polypodii rhizoma, Polypodium vulgare L., C: ongoing call for scientific data
Submitted by Anonymous (not verified) on 13 March 2025 - 9:44
Herbal medicinal product: Polypodii rhizoma, Polypodium vulgare L., C: ongoing call for scientific data
EMA Management Board elects new chair
Submitted by Anonymous (not verified) on 13 March 2025 - 9:30
EMA Management Board elects new chair
Agenda of the HMPC meeting 17-19 March 2025
Submitted by Anonymous (not verified) on 13 March 2025 - 9:10
Agenda of the HMPC meeting 17-19 March 2025
Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Infections and infestations, PIP number: P/0028/2024
Submitted by Anonymous (not verified) on 12 March 2025 - 16:30
Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Infections and infestations, PIP number: P/0028/2024